Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

• Status: Terminated
• Trial end date: 2009-07-01

Summary

This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Ranibizumab; Verteporfin